

LARS KLARESKOG PUBLICATIONS 2009**Peer-reviewed articles**

1. Ding B, Padyukov L, Lundström E, Seielstad M, Plenge RM, Oksenberg J, Gregersen PK, Alfredsson L, Klareskog L Dense SNP mapping across the MHC in rheumatoid arthritis reveals major differences between disease subsets defined by presence/absence of antibodies to citrullinated protein antigens (ACPA) and identifies *HLA-DPB1* as an independent risk locus for ACPA-positive disease *Arthritis Rheum*; 2009 Jan;60(1):30-8
2. Liao KP, Gunnarsson M, Källberg H, Ding B, Plenge RM, Padyukov L, Karlson EW, Klareskog L, Askling J, Alfredsson L Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis. *Arthritis Rheum*. 2009 60(3):653-60.
3. Lundström E, Källberg H, Smolnikova M, Ding B, Rönnelid J, Alfredsson L, Klareskog L, Padyukov L Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. *Arthritis Rheum*. 2009 Mar 30;60(4):924-930.
4. Bengtsson C, Theorell T, Klareskog L, Alfredsson L Psychosocial Stress at Work and the Risk of Developing Rheumatoid Arthritis: Results from the Swedish EIRA Study. *Psychother Psychosom*. 2009 Mar 24;78(3):193-194
5. Stolt P, Yahya A, Bengtsson C, Källberg H, Rönnelid J, Lundberg I, Klareskog L, Alfredsson L, Study Group T. Silica exposure among male current smokers is associated with a high risk of developing ACPA positive rheumatoid arthritis. *Ann Rheum Dis*. 2009 Dec 4
6. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Forede CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? *Arthritis Rheum*. 2009 Nov;60(11):3180-9.
7. International MHC and Autoimmunity Genetics Network, Rioux JD, Goyette P, Vyse TJ, Hammarström L, Fernando MM, Green T, De Jager PL, Foisy S, Wang J, de Bakker PI, Leslie S, McVean G, Padyukov L, Alfredsson L, Annese V, Hafler DA, Pan-Hammarström Q, Matell R, Sawcer SJ, Compston AD, Cree BA, Mirel DB, Daly MJ, Behrens TW, Klareskog L, Gregersen PK, Oksenberg JR, Hauser SL. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. *Proc Natl Acad Sci U S A*. 2009 Nov 3;106(44):18680-5.
8. Holmqvist ME, Wedrén S, Jacobsson LT, Klareskog L, Nyberg F, Rantapää-Dahlqvist S, Alfredsson L, Askling J. No increased occurrence of ischemic heart disease prior to the onset of rheumatoid arthritis: results from two Swedish population-based rheumatoid arthritis cohorts. *Arthritis Rheum*. 2009 Oct;60(10):2861-9.
9. Rosell M, Wesley AM, Rydin K, Klareskog L, Alfredsson L; EIRA study group Dietary fish and fish oil and the risk of rheumatoid arthritis. *Epidemiology*. 2009 Nov;20(6):896-901.
10. Tian C, Kosoy R, Nassir R, Lee A, Villoslada P, Klareskog L, Hammarström L, Garchon HJ, Pulver AE, Ransom M, Gregersen PK, Seldin MF European population genetic

- substructure: further definition of ancestry informative markers for distinguishing among diverse European ethnic groups. *Mol Med*. 2009 Nov-Dec;15(11-12):371-83.
11. Lundström E, Källberg H, Alfredsson L, Klareskog L, Padyukov L. Gene-environment interaction between the DRB1 shared epitope and smoking in the risk of anti-citrullinated protein antibody-positive rheumatoid arthritis: all alleles are important. *Arthritis Rheum*. 2009 Jun;60(6):1597-603.
 12. Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. *Arthritis Res Ther*. 2009;11(3):R76.
 13. Lundström E, Källberg H, Smolnikova M, Ding B, Rönnelid J, Alfredsson L, Klareskog L, Padyukov L. Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. *Arthritis Rheum*. 2009 Apr;60(4):924-30.
 14. Bengtsson C, Theorell T, Klareskog L, Alfredsson L. Psychosocial stress at work and the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. *Psychother Psychosom*. 2009;78(3):193-4.
 15. Jagodic M, Colacios C, Nohra R, Dejean AS, Beyeen AD, Khademi M, Casemayou A, Lamouroux L, Duthoit C, Papapietro O, Sjöholm L, Bernard I, Lagrange D, Dahlman I, Lundmark F, Oturai AB, Soendergaard HB, Kemppinen A, Saarela J, Tienari PJ, Harbo HF, Spurkland A, Ramagopalan SV, Sadovnick DA, Ebers GC, Seddighzadeh M, Klareskog L, Alfredsson L, Padyukov L, Hillert J, Clanet M, Edan G, Fontaine B, Fournié GJ, Kockum I, Saoudi A, Olsson T. A role for VAV1 in experimental autoimmune encephalomyelitis and multiple sclerosis. *Science Transl Med*. 2009 Dec 9;1(10)
 16. Raychaudhuri S et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. *Nature Genetics*. 2009 Dec;41(12):1313-8.
 17. Mahdi H, Fisher BA, Källberg H, Plant D, Malmström V, Rönnelid J, Charles P, Ding B, Alfredsson L, Padyukov L, Symmons DP, Venables PJ, Klareskog L, Lundberg K. Specific interaction between genotype, smoking and autoimmunity to citrullinated alpha-enolase in the etiology of rheumatoid arthritis. *Nature Genetics*. 2009 Dec;41(12):1319-24.

Reviews

1. Klareskog L, Wedrén S, Alfredsson L. On the origins of complex immune-mediated disease: the example of rheumatoid arthritis. *J Mol Med*. 2009 Jan 22.
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. *Lancet*. 2009 Feb 21;373(9664):659-72
3. af Klint E, Catrina AI, Matt P, Neregråd P, Lampa J, Ulfgrén AK, Klareskog L, Lindblad S. Evaluation of arthroscopy and macroscopic scoring. *Arthritis Res Ther*. 2009;11(3):R81.